


A case of hematidrosis complicated with von Willebrand disease

Masahiro Takeyama, Shoko Furukawa, Kenichi Ogiwara and Keiji Nogami Department of Pediatrics, Nara Medical University, Kashihara, Nara, Japan



INTRODUCTION

- √ von Willebrand disease (VWD) is caused by quantitative or qualitative abnormalities of von Willebrand factor (VWF), which plays an important role in hemostasis.
- ✓ VWD can be divided into three major categories, type 1, 2, and 3, based on VWF activity, antigen levels, and multimer analysis¹¹⟩. Type 1 is a (partial) quantitative decrease in VWF with qualitatively normal VWF, type 2 is qualitative abnormalities in VWF, and type 3 is complete deficiency. Type 1 is the most) common ²¹⟩.
- ✓ In VWD, platelet adhesive capacity is mainly impaired, resulting in epistaxis, purpura, and hematomas, oral bleeding, abnormal menstrual bleeding, gastrointestinal bleeding, hematuria, and other recurrent mucous membrane and skin bleeding.
- Hematidrosis is extremely rare disease characterized by bloody sweating from non-traumatized skin and mucous membranes. There have been only a few dozen cases reported worldwide ³⁾. The cause and pathogenesis of hemosiderosis are not known, but it is said that it can be caused by extreme stress, such as death threats.
- √ Here, we report 14-year-old girl of hematidrosis complicated
 with VWD.

AIM

To diagnose whether the patient's bleeding symptoms are due to VWD or hematidrosis.

METHOD

We showed her clinical course and analyzed her blood samples. The presentation of this case and the publication of the photographs have been approved by the patient and the parents.

Comprehensive coagulation function analysis using rotational thromboelastometry (ROTEM), total thrombus-formation analysis system (T-TAS), and Multiplate were performed to evaluate her coagulation function.

REFERENCES

- 1) Thromb Haemost, 71, 520-525, 1994,
- 2) Jpn J Thromb Hemost, 32, 413-481, 2021
- 3) J Dermatol, 47, 166-168, 2020

CONTACT INFORMATION

Masahiro Takeyama, MD, PhD email; mtake@naramed-u.ac.jp

RESULTS

[Patient] 14 years old, female

[Family History] The 3rd of 3 children, no bleeding episode

[Past History] Asthma bronchitis and Atopic dermatitis. No hemostatic abnormalities were noted at the time of tonsillectomy at age 9, surgery for tarsal fusion and fracture of the right forearm (cast immobilization only) at age 11.

[Present History]

Redness and swelling around the eyes, bleeding and pain in the oral cavity appeared upon waking up in Feb., X-1. She visited a dermatologist and an oral surgeon at a local doctor, but the cause was unknown (allergy or self-injury was suspected). In February, X, her bleeding symptoms worsened, and she was unable to attend school due to oral pain and bleeding symptoms. She visited her previous doctor for a thorough examination, and a blood test showed VWF activity was 29% and VWD was suspected. She had oral and nasal bleeding once every 4 to 5 days. She was referred to our department for a thorough examination. The effect of tranexamic acid prescribed by the previous doctor was not clear.



Bleeding in the cheeks, forehead, and other parts of the face and oral cavity (left), and bleeding from the posterior portion of the auricle (right)

Laboratory tests			
Blood type	0	VWF:RCo (%)	29.0
WBC (/µL)	7200	VWF:Ag (%)	41.3
RBC (×104/μL)	429	D-dimer (µg/mL)	0.5
Hb (g/dL)	13.6	Plasminogen (%)	98
Plt (×104/μL)	20.2	α2-PI (%)	118
PT (sec) (<11.4sec)	11.4	Lupus anticoagulant	1.1
APTT (sec) (<32.4sec)	39.9	Anti-cardiolipin IgG Ab (U/mL)	≦8
FVIII:C (IU/dL)	71	Total PAI (ng/mL)	18
FIX:C (IU/dL)	81		



According to the laboratory tests, she was diagnosed with VWD type 1.

Treatment	DI	Prop	ranolo	l →				
Bleeding sympto	m							
Nose or oral cavit	у шш	14	1	118.111	444			4 4
Face	A	11		HILL	118.1			
Palm and Sole Umbilicus			4	١,	14			
	1	No ble	eding	on ho	oliday	/s		
	pr.,	No ble		Ja	oliday in., +1		Jul.	Oct.

Patient	Control (ave ± SD)		
932	938 ± 128		
448	331 ± 86		
43	43 ± 5		
	932		

- The episodes usually happed before going to junior high school in the morning and no bleeding symptoms were seen during the holidays.
- √ Each episode lasted several hours and was usually self-limited.
- DDAVP (1-deamino-8-D-arginine vasopressin) was administered as a treatment for the bleedings, but no apparent effect was observed although VWF:RCo was elevated after administration of DDAVP.
- Comprehensive coagulation function analysis using rotational thromboelastometry (ROTEM), total thrombus-formation analysis system (T-TAS), and Multiplate were performed to evaluate her coagulation function and showed the almost normal range except for PL in T-TAS and ristocetin in Multiplate.
- V Oral propranolol was commenced because the drug is considered effective for hematidrosis. However, no immediate effects were observed after propranolol administration.
- √ She was referred to psychiatrist and her psychiatric disorders at school was revealed.
- √ The frequency of bleeding decreased remarkably after graduation from junior high school.

				piadina			
T-TAS		Patient	Control (ave ± SD)	Multiplate		Patient	Control (ave ± SD)
PL12	T-10 (min)	4.3	4.4 ± 1.4		AUC (U)	5	108 ± 35.3
	T-30	9.2	5.7 ± 1.6	Ristocetin	Aggregation	13.5	225 ± 58.6
	(min)				Velocity	3.0	15.7 ± 3.7
	AUC (/min)	108	265 ± 93.7		AUC (U)	73	77.4 ± 16.8
PL24 (r (r A	T-10 (min)	1.3	3.2 ± 1.1		Aggregation	140	151 ± 29.4
	T-30 (min)	2.4	4.0 ± 1.6		Velocity	14.7	15.7 ± 3.7
	ALIC			AUC (U)	103	98.9 ± 21.1	
	(/min)	279	376 ± 85	Collagen	Aggregation	190	185 ± 37.9
AR	T-10 (min)	14.1	12.5 ± 2.2		Velocity	25.8	23.6 ± 5.0
	T-80 (min)	19.5	17.2 ± 2.8			А	UC; area under the curve
	ALIC			1			

CONCLUSIONS

 1222 ± 194

1044

(/min)

We report a case of VWD type 1 complicated with hematidrosis, possibly due to not bleeding disorder by VWD type 1 but mental stress at junior high school.